Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq:UTMD) reports that for the third calendar quarter (3Q) of 2007 compared to 3Q 2006, consolidated sales were up 1%, gross profits were the same, operating profits

City, Utah - Utah Medical Products, Inc. (Nasdaq:UTMD) reports that for the

third calendar quarter (3Q) of 2007 compared to 3Q 2006, consolidated sales

up 1%, gross profits were the same, operating profits were down 1%, net income

was up 1%, and earnings per share (eps) were up

2007, UTMD achieved the following profit margins:

3Q 2007 sales to 3Q 2006 global sales in product categories, obstetrics product

sales were down 8%, neonatal product sales were down 4%, gynecology/

electrosurgery product sales were up 2%, and blood pressure monitoring/

components sales were up 25%. Domestic sales in 3Q 2007 were down 8% while

international sales were up 31%, compared to the same quarter last

year. Although trade shipments from UTMD Ireland were up 10% in EURO

terms, they were up 19% in U.S. Dollar terms because of a weaker U.S.

gross profit margin in 3Q 2007 was 56.0% compared to 56.7% in 3Q 2006, primarily

because the current quarter's sales increases were provided by international

shipments at lower than average prices offsetting decreases in domestic sales.

Operating expenses in 3Q 2007 were 17.7% of sales compared to 17.6% of sales

3Q 2006. Included in 3Q 2007 operating expenses, the impact of

expensing options was $25,300 compared to $32,700 in 3Q 2006.

UTMD's income tax provision rate was 34.5% in 3Q 2007 compared to 33.3% in 3Q

income was up 1%, consistent with the increase in sales. Eps, which

benefited from continued share repurchases, were $.51 in 3Q 2007 compared to

able to achieve 3Q 2007 financial performance generally a little better than

2006 results despite $320,000 lower domestic sales of intrauterine pressure

catheters and vacuum-assisted delivery devices (obstetrics products) for

hospital L&D units, and despite inflationary pressure in direct materials

and direct labor manufacturing costs. The lower obstetrics sales were

due to price reductions and to group purchasing organization administrative

arrangements limiting physician choice of devices used in L&D.

three quarters year-to-date, or nine months (9M), in 2007 to 9M 2006,

consolidated sales were the same, gross profits were down 1%, operating profits

were up 2%, net income was down 2%, and earnings per share (eps) were down

1%. In 9M 2007, increases in international sales have offset the

decreases in domestic sales. Net income was down even though

operating profits were up because non-recurring capital gains from investments

were lower in 9M 2007, and the consolidated income tax provision rate was almost

one percentage point higher.

the most recent 4 calendar quarters were $2.00. Looking forward to

the end of the year, management projects that 2007 eps performance will fall

short of the record $2.02 eps results achieved in 2006. $1.99/ share

in 2007 eps now appears most likely.

ratios as of September 30, 2007 which may be of interest to shareholders

in Receivables (based on 3Q sales activity) = 49

Inventory Turns (based on 3Q CGS) = 3.9

ROE = 12% (after dividends)

from unexercised option shares added to actual weighted average outstanding

shares for purposes of calculating eps was 57,300 in 3Q 2007 compared to 91,800

in 3Q 2006, and 63,800 in 9M 2007 compared to 102,000 in 9M 2006. The

actual number of outstanding shares at the end of 3Q 2007 was 3,915,900 which

included 3Q employee option exercises of 2,000 shares and 3Q share repurchases

of 10,000 shares. The average price paid by the Company to repurchase shares

the open market during 3Q 2007 was $30.05 including commissions. Year-to-date

purchases through 9M 2007 have been 50,700 shares at an average per share cost

of $30.97. The total number of outstanding unexercised options at September

2007 was 219,100 shares at an average exercise price of $21.46/ share, including

shares awarded but not vested. This compares to 269,100 unexercised option

shares outstanding at the end of 3Q 2006.

are cautioned that this press release may contain forward looking statements,

and that actual events may differ from those projected. Risk factors

that could cause results to differ materially from those projected include

market acceptance of products, timing of regulatory approval of new products,

regulatory intervention in current operations, the Company's ability to

efficiently manufacture, market, and sell its products, among other factors

have been outlined in UTMD=s

disclosure filings with the SEC. The SEC Form 10-Q for 3Q 2007 will

be filed with the SEC by November 9.

Medical Products, Inc., with particular interest in health care for women and

their babies, develops, manufactures, assembles and markets a broad range of

disposable and reusable specialty medical devices designed for better health

outcomes for patients and their care-providers. For more information

about Utah Medical Products, Inc., visit UTMD=s

Medical Products, Inc.

STATEMENT, Third Quarter (3 months ended September 30)

thousands except earnings per share):

STATEMENT, First Nine Months (9 months ended September 30)

thousands except earnings per share):